Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 3/20 | 0.38 |
| ▸ | ACACB | O00763 | 4/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | APEX1 | P27695 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | PIK3CD | O00329 | 4/20 | 0.34 |
| ▸ | PIK3CA | P42336 | 4/20 | 0.34 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.33 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.32 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20069359 | 0.90 | RET (0.39) | RETACACBLMNACYP2C9TSHR | |
| SCHEMBL20152047 | 0.82 | HRH3 (0.45) | RETACACBPIK3CDPIK3CA | |
| SCHEMBL20147969 | 0.82 | RET (0.41) | RETLMNACYP2C9TSHRAPEX1 | |
| SCHEMBL20069364 | 0.80 | HRH3 (0.44) | RET | |
| SCHEMBL20158636 | 0.78 | ACACB (0.36) | RETACACBPDGFRBPDGFRA | |
| SCHEMBL20069356 | 0.76 | PIK3CD (0.42) | RETACACBPIK3CDPIK3CA | |
| SCHEMBL22856983 | 0.75 | OXTR (0.41) | ACACB | |
| SCHEMBL20069138 | 0.74 | RET (0.40) | RETACACBPIK3CDPIK3CA | |
| SCHEMBL29594733 | 0.73 | IKBKB (0.44) | PDGFRBPDGFRA | |
| SCHEMBL20321361 | 0.73 | IKBKB (0.44) | PDGFRBPDGFRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10881652-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2021-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10881652-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | RET, BRAF, RAF1 | RET 1/4885ACACB 4835/4885LMNA 1968/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.